Saturday 17 October 2026 Export ACET’s income statement to Excel — free account

Adicet Bio, Inc.

In the quarter to June 2026, EPS grew 63.4% and free cash flow grew 24.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.57 0.57 −11.09%

Follow ACET

Alert me

Market cap: $48.1M
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: 4/9
Altman Z: 4.96
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.60

Total sells 0.67

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	—	—	—	—	—	—

Insider Ownership 23.50%

Capital & Financial Ratios $m

Market Cap 48.12

Revenue 38.70

Net Income (98.97)

Free Cash Flow (84.97)

Net Debt (117.56)

Current Ratio 6.71

Debt/Equity 0.01

P/E ratio 0.00

Fwd P/E (0.43)

P/S ratio 1.27

P/B ratio 0.41

Past 5Y EPS Growth —

This Y EPS Growth 62.49%

Next Y EPS Growth 36.47%

Next Y revenue growth (90.00%)

Next 5Y EPS Growth 63.23%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.84%

10-year low 10-year high

P/B against its own 10 years 15.57%

10-year low 10-year high

EV/FCF against its own 10 years 44.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	0.09	0.07 0.01 0.01
2017	0.26	0.07 0.07 0.07 0.07
2016	0.25	0.06 0.06 0.07 0.07

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	160	176	159	118
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	162	180	161	121

	2023	2024	2025	Q'26
Payables	3	5	5	4
ST’ Debt	—	—	—	—
Other	13	11	—	—
	19	19	22	18

Compound Annual Growth %

	10y	5y	3y
Sales	—	6.90%	192.85%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	7.71%	(18.34%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	25	—	—	—	25
’21	—	5	3	5	10
’20	2	7	3	5	18
’19	—	—	—	8	1

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(20)	—	—	—
’25	(25)	(27)	(22)	(21)	(95)
’24	(23)	(23)	(22)	(24)	(92)
’23	(24)	(25)	(21)	(23)	(94)
’22	4	(15)	(15)	(19)	(45)
’21	(15)	(13)	(10)	(13)	(51)
’20	(8)	(12)	(8)	(13)	(42)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(20)	—	—	—
’25	(27)	(27)	(23)	(21)	(97)
’24	(23)	(24)	(22)	(24)	(93)
’23	(26)	(26)	(22)	(24)	(98)
’22	1	(18)	(20)	(25)	(62)
’22	—	—	—	—	(45)
’21	(16)	(15)	(17)	(17)	(64)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.88)	(1.99)	—	—	—
’25	(4.96)	(5.44)	(4.64)	(2.94)	(16.95)
’24	(5.60)	(5.28)	(5.44)	(5.12)	(21.28)
’23	(11.52)	(12.00)	(18.56)	(11.04)	(52.96)
’22	1.60	(8.96)	(8.48)	(11.52)	(27.20)
’21	(13.12)	(5.44)	(7.04)	(7.52)	(32.00)
’20	(33.18)	(62.14)	(45.44)	(7.36)	(80.16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	816.48	105.28	96.32	100.00	120.96	17.60	12.96	7.15	Analyst estimates 2026–2028 Powerpack
	High	—	—	2,362.86	1,339.52	347.20	284.80	349.92	152.40	60.32	17.76
People
People	Employees	7	7	21	18	102	102	132	143	152	102
	Revenue/emp, $m	0.00	0.00	0.39	0.06	0.18	0.10	0.19	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	8	1	18	10	25	—	—	—
	Gross margin, %	—	0.00	100.00	100.00	100.00	100.00	100.00	—	—	—
	EBT	0	(34)	(10)	(28)	(39)	(62)	(70)	(143)	(117)	(117)
	EBT margin, %	0.00	0.00	(120.87)	(2,826.03)	(220.59)	(638.48)	(279.27)	0.00	0.00	0.00
	Net income	0	(34)	(9)	(28)	(37)	(62)	(70)	(143)	(117)	(117)
	Depreciation	0	0	1	1	1	2	3	26	5	2
Per share, $
Per share, $	Revenue	0.00	0.00	67.22	7.44	39.13	5.03	9.73	0.00	0.00	0.00
	Earnings	0.00	(942.76)	(76.42)	(210.48)	(80.16)	(32.00)	(27.20)	(52.96)	(21.28)	(16.95)
	Cash flow	0.00	(306.84)	(149.38)	(208.54)	(90.82)	(26.39)	(17.44)	(34.84)	(16.82)	(13.82)
	Capex	0.00	(1.23)	(7.20)	(7.12)	(2.16)	(6.74)	(6.54)	(1.66)	(0.20)	(0.25)
	Free cash flow	0.00	(308.07)	(156.58)	(215.66)	(92.99)	(33.13)	(23.97)	(36.50)	(17.02)	(14.07)
	Book value	0.00	(891.87)	856.24	(451.50)	240.06	156.70	113.86	63.26	33.98	23.10
	Shares, m	4	0	0	0	0	2	3	3	5	7
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	P/S	—	—	0.00	0.00	5.74	55.64	9.10	—	—	—
	P/B	—	—	1.13	0.00	0.94	1.79	1.20	—	—	—
	EV/Sales	—	—	0.00	0.00	1.60	29.10	2.92	—	—	—
	EV/FCF	—	—	(0.50)	1.39	(0.67)	(4.42)	(1.83)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	0	(11)	(18)	(28)	(42)	(51)	(45)	(94)	(92)	(95)
	Capex	0	0	(1)	(1)	(1)	(13)	(17)	(4)	(1)	(2)
	Free cash flow	0	(11)	(19)	(29)	(43)	(64)	(62)	(98)	(93)	(97)
Balance, $m
Balance, $m	Working capital	—	50	104	49	78	266	241	143	161	139
	Total debt	—	—	—	114	20	19	19	—	—	1
	Net debt	—	(53)	(108)	(62)	(95)	(278)	(258)	(160)	(176)	(158)
	Shareholders’ equity	—	(32)	104	(60)	110	303	292	170	187	159
Returns, %
Returns, %	ROA	0.00	(122.40)	(11.26)	(29.38)	(31.16)	(25.16)	(20.84)	(53.03)	(54.79)	(56.62)
	ROIC	—	0.00	0.00	0.00	(161.01)	(150.07)	(130.74)	(908.10)	(773.91)	(5,773.17)
	ROE	0.00	105.79	(25.73)	(128.37)	(148.31)	(30.03)	(23.44)	(61.69)	(65.65)	(67.55)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CRBU Caribou Biosciences, Inc.	$49.8M	— (loss-making)	— (loss-making)	−43.79% (below 0%: shrinking)	n/m	−33.16% (below 0%: shrinking)	100.00%	(1,690.39%)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$49.3M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
HYPD Hyperion DeFi, Inc.	$49.0M	— (loss-making)	3.6×	+2,333.33% (above 0%: growing)	n/m	+86.82% (above 0%: growing)	100.00%	8,668.63%	Compare
HOWL Werewolf Therapeutics, Inc.	$48.5M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
ELTX Elicio Therapeutics, Inc.	$48.2M	— (loss-making)	— (loss-making)	−55.27% (below 0%: shrinking)	n/m	+8.77% (above 0%: growing)	0.00%	0.00%	Compare
ACET Adicet Bio, Inc.	$48.1M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$47.6M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)	Compare
Median of peers	$48.3M	—	—	+166.67%	—	+16.47%	80.00%	0.00%

All 614 Biotechnology stocks →

Adicet Bio, Inc. (ACET) key facts

Adicet Bio, Inc. (ACET) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ACET traded at $4.57, a market capitalization of $48.1 million.
Return on equity was −67.6% and debt-to-equity 0.01.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 4.96 (safe zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.